폐 전이 동반 연부육종 시장 : 인사이트, 역학, 예측(-2034년)

Key Highlights:

• Metastasis is not uncommon; in fact, approximately 40% to 50% of individuals with STS will eventually develop metastatic disease. Among all possible sites, the lungs are by far the most common destination for metastases, accounting for nearly 80% of first metastatic occurrences.
• Patients who present with STS of the lower extremity, higher grade, and either leiomyosarcoma, spindle cell, or synovial cell sarcoma were more likely to present with lung metastases.
• Pulmonary metastasectomy is widely accepted as a standard treatment approach for lung metastases from STS.
• While metastatic STS carries a poorer prognosis, aggressive treatments like metastasectomy and stereotactic body radiation therapy (SBRT) can improve survival, which ranges from 26% to 30%.
• Patients with lung metastases had worse survival than patients without metastases. However, survival was better in patients with isolated lung metastases than in those with any combination of lung, bone, brain, and/or liver metastases.
• There are currently no therapies specifically approved for STS with lung metastases. While various systemic therapies are used to manage metastatic STS, none are uniquely indicated for lung metastases. Annamycin (Moleculin Biotech), Volrustomig (MEDI5752) + SBRT (Institut Claudius Regaud/AstraZeneca) is the only known drug in active clinical development targeting this specific population.
• In June 2025, Moleculin reported positive topline efficacy results from US Phase Ib/II clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma with lung metastases (MB-107).

DelveInsight's "Soft tissue sarcoma (STS) with Lung Metastasis Market- Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of STS with lung metastasis epidemiology, market, and clinical development in STS with lung metastasis with lung metastasis. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the STS with lung metastasis with lung metastasis market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

The STS with lung metastasis with lung metastasis market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted STS with lung metastasis with lung metastasis market size from 2020 to 2034 in 7MM. The report also covers current STS with lung metastasis with lung metastasis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Soft Tissue Sarcoma with Lung Metastasis Understanding and Treatment Algorithm

Soft Tissue Sarcoma with Lung Metastasis Overview and Diagnosis

Soft tissue sarcoma (STS) is a diverse group of rare malignant tumors that originate in the mesodermal tissues-such as fat, muscle, blood vessels, deep skin layers, tendons, and ligaments-that support and connect various parts of the body. While these tumors can occur anywhere, they most often begin in the arms or legs, but can also develop in the trunk, head and neck, internal organs, or the retroperitoneal space (the area behind the abdominal cavity). One of the major challenges in STS is its potential to spread beyond the original tumor site. Metastasis is not uncommon; in fact, approximately 40% to 50% of individuals with STS will eventually develop metastatic disease. Among all possible sites, the lungs are by far the most common destination for metastases, accounting for nearly 80% of first metastatic occurrences. When STS spreads to the lungs, it typically signals a more advanced stage of the disease, requiring a shift in treatment goals-from curative intent to controlling disease progression, alleviating symptoms, and extending survival. STS with lung metastasis is diagnosed through a combination of imaging scans, biopsies, and sometimes blood tests. Imaging, like chest X-rays, CT scans, or MRIs, can reveal the presence of tumors in the lungs. Biopsies, where tissue samples are examined under a microscope, confirm the diagnosis and determine the specific type of sarcoma.

The STS with lung metastasis report provides an overview of STS with lung metastasis pathophysiology, and diagnostic approaches, along with a real-world scenario of a patient's journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Soft tissue sarcoma with lung metastasis Treatment

Pulmonary metastases are a sign of advanced disease and are always a challenge in the management of oncologic patients. The mainstay of treatment is the surgical resection of all metastatic nodules which offers a potentially curative option and a significant survival advantage. In the setting of metastatic sarcoma, lung involvement is frequent, and the disease tends to recur with a significantly higher pattern than in any other tumor type. Multiple or even extended operations are often necessary. Alongside the operative approach, medical therapy has been reported with variable results. Currently, single-agent chemotherapy or combinations are reserved for patients with chemosensitive histology or patients considered for multimodality therapy. The role of immunotherapy, instead, despite promising results, is still under investigation. Radiotherapy has been boosted in recent years, with the spread of stereotactic body radiation therapy which overwhelmed the traditional sarcomas' radioresistance.

Soft tissue sarcoma with lung metastasis Epidemiology

As the market is derived using a patient-based model, the STS with lung metastasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of STS, total incident cases of STS with lung metastasis, gender-specific cases of STS with lung metastasis, age-specific cases of STS with lung metastasis, and total treated cases of STS with lung metastasis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

• As per SEER database data from 14,520 patients diagnosed with STS between 2010 and 2018. Of the 13,372 patients with STS, 7.9% had lung metastases at diagnosis.
• Undifferentiated pleomorphic sarcoma, leiomyosarcoma, and rhabdomyosarcoma were the most common STS presenting with lung metastasis.
• The risk of metastasis is largely driven by tumor grade; approximately 60% of patients with high-grade tumors will develop lung metastases, with the vast majority occurring within 2 years of primary tumor resection.

Soft tissue sarcoma with lung metastasis Drug Chapters

The drug chapter segment of the STS with lung metastasis report encloses a detailed analysis of STS with lung metastasis marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the STS with lung metastasis's pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Emerging Drugs

Annamycin: Moleculin Biotech

Annamycin is a next-generation anthracycline being developed by Moleculin Biotech for hard-to-treat cancers, including STS with lung metastases. Unlike traditional anthracyclines, Annamycin has shown no evidence of cardiotoxicity in clinical trials, allowing for potentially higher cumulative dosing beyond FDA-set lifetime limits. This could make it a safer and more potent option in advanced STS, where standard anthracycline use is often restricted due to cardiac risks. The drug has received US FDA Orphan Drug and Fast Track Designations specifically for STS with lung metastases and is currently being evaluated in a Phase Ib/II clinical trial.

Volrustomig (MEDI5752): Institut Claudius Regaud/AstraZeneca

MEDI5752 is an anti PD-1/CTLA-4 bispecific antibody developed by AstraZeneca. The company is conducting Phase I trial of MEDI5752 in combination with SBRT delivered on one lung metastatic lesion, in patients with metastatic soft tissue sarcoma.

Soft tissue sarcoma with lung metastasis Market Outlook

The gold standard for patients with localized STSs is surgical-wide resection with oncologic margins. In contrast, STS patients with metastatic lesions are treated by systemic chemotherapy, radiation, and possibly with resection of the primary tumor or metastatic lesions. Doxorubicin, the first-line palliative chemotherapy, is recommended as a therapeutic option for the majority of STS patients with Lung Metastases. Pulmonary metastasectomy is also a proven standard approach for the management of STS patients with LM, and some published studies have indicated that 5-year overall survival (OS) ranges from 43% to 50.9% in patients following this procedure. In addition, Matsuoka et al reported surgical resection of a primary tumor in the extremities could improve survival for metastatic STS patients. Despite efforts to improve the clinical outcome of these patients, the prognosis remains poor.

There are currently no therapies specifically approved for STS with lung metastases. While various systemic therapies are used to manage metastatic STS, none are uniquely indicated for lung metastases. Few companies are conducting trials for this segment such as Moleculin Biotech, AstraZeneca, and others.

• In 2024, the United States accounts for the largest market size of STS with lung metastasis, in comparison to EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Among the EU4 and the UK, Germany had the highest market size, while Spain had the smallest market size for STS with lung metastasis in 2024.

Soft tissue sarcoma with lung metastasis Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024-2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Soft tissue sarcoma with lung metastasis Cancer Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for STS with lung metastasis emerging therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as UT Health San Antonio MD Anderson Cancer Center, University of Michigan, and Sarcoma Oncology Center etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or STS with lung metastasis market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of STS with lung metastasis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the STS with lung metastasis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM STS with lung metastasis market.

Soft tissue sarcoma with lung metastasis Report Insights

• Patient Population
• Therapeutic Approaches
• STS with lung metastasis Pipeline Analysis
• STS with lung metastasis Market Size and Trends
• Existing and future Market Opportunity

Soft tissue sarcoma with lung metastasis Report Key Strengths

• 10-Years Forecast
• 7MM Coverage
• STS with lung metastasis Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Soft tissue sarcoma with lung metastasis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What is the historical and forecasted STS with lung metastasis patient pool/patient burden in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which combination treatment approaches will have a significant impact on the STS with lung metastasis drug treatment market size?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of STS with lung metastasis?
• How many companies are developing therapies for the treatment of STS with lung metastasis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the STS with lung metastasis market.
• Insights on patient burden/disease Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Epidemiology and Market Forecast Methodology

4. Soft tissue sarcoma with lung metastasis: Market Overview at a Glance

• 4.1. Market Size (%) of Soft tissue sarcoma with lung metastasis in 2020
• 4.2. Market Size (%) of Soft tissue sarcoma with lung metastasis in 2034

5. Executive Summary

6. Key Events

7. Disease Background and Overview: Soft tissue sarcoma with lung metastasis

• 7.1. Introduction
• 7.2. Causes
• 7.3. Pathophysiology
• 7.4. Symptoms
• 7.5. Risk Factor
• 7.6. Diagnosis

8. Treatment and Management

• 8.1. Treatment Guidelines

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total incident cases of Soft tissue sarcoma with lung metastasis:7MM
• 9.4. The United States
  • 9.4.1. Total incident cases of Soft tissue sarcoma
  • 9.4.2. Total incident cases of Soft tissue sarcoma with lung metastasis
  • 9.4.3. Gender-specific cases of Soft tissue sarcoma with lung metastasis
  • 9.4.4. Age-specific cases of Soft tissue sarcoma with lung metastasis
  • 9.4.5. Total treated cases of Soft tissue sarcoma with lung metastasis
• 9.5. EU4 and the UK
  • 9.5.1. Total incident cases of Soft tissue sarcoma
  • 9.5.2. Total incident cases of Soft tissue sarcoma with lung metastasis
  • 9.5.3. Gender-specific cases of Soft tissue sarcoma with lung metastasis
  • 9.5.4. Age-specific cases of Soft tissue sarcoma with lung metastasis
  • 9.5.5. Total treated cases of Soft tissue sarcoma with lung metastasis
• 9.6. Japan
  • 9.6.1. Total incident cases of Soft tissue sarcoma
  • 9.6.2. Total incident cases of Soft tissue sarcoma with lung metastasis
  • 9.6.3. Gender-specific cases of Soft tissue sarcoma with lung metastasis
  • 9.6.4. Age-specific cases of Soft tissue sarcoma with lung metastasis
  • 9.6.5. Total treated cases of Soft tissue sarcoma with lung metastasis

10. Patient Journey

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Annamycin: Moleculin Biotech
  • 11.2.1. Product Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Development Activities
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst View
• 11.2. Volrustomig (MEDI5752): Institut Claudius Regaud/AstraZeneca
  • 11.2.1. Product Description
  • 11.2.2. Other Development Activities
  • 11.2.3. Clinical Development Activities
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst View

12. Soft tissue sarcoma with lung metastasis: Market Size

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptake
• 12.5. Total Soft tissue sarcoma with lung metastasis Market Analysis: 7MM
• 12.6. United States
  • 12.6.1. Total Market Size of Soft tissue sarcoma with lung metastasis in the United States
  • 12.6.2. Market Size of Soft tissue sarcoma with lung metastasis by Therapies in the United States
• 12.7. EU4 and the UK
  • 12.7.1. Total Market Size of Soft tissue sarcoma with lung metastasis in EU4 and the UK
  • 12.7.2. Market Size of Soft tissue sarcoma with lung metastasis by Therapies in EU4 and the UK
• 12.8. Japan
  • 12.8.1. Total Market Size of Soft tissue sarcoma with lung metastasis in Japan
  • 12.8.2. Market Size of Soft tissue sarcoma with lung metastasis by Therapies in Japan

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement

• 16.1. United States
• 16.2. EU4 and the UK
• 16.3. Japan

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight